New research indicates that a blood test that is relatively simple can predict a patient’s risk of suffering a future heart attack. Physicians can determine what patients need more aggressive testing and treatment as well as those who are low – risk patients so they can avoid unnecessary tests. Before this research was completed it was not possible to differentiate a patient with heart disease who was at risk for a future heart attack versus a patient who was not likely to suffer future cardiac events. Therefore, cardiologists are now able to quickly treat the at risk patients and monitor those at lower risk.
Emory cardiologist Arshed Quyyumi, MD and Stephen E. Epstien, MD of MedStar Heart Institute are the senior authors of this research. During the research they studied over 3400 cardiology patients who had confirmed coronary artery disease or suspected disease. Each patient was followed for over 2 years.
Read the full news article and more about the new findings that were published in the Journal of American College of Cardiology.
About Arshed Quyyumi, MD
Dr. Quyyumi is a Professor, Division of Cardiology, Emory University School of Medicine, Co-Director, Emory Clinical Cardiovascular Research Institute (ECCRI)
Dr. Arshed A. Quyyumi has been involved in clinical translational research in cardiovascular diseases for over 25 years. Dr. Quyyumi received his undergraduate degree in Pharmacology and medical degree from the University of London, England. He completed his residency at Guy’s and Royal Free Hospitals in London, and cardiology fellowships at National Heart Hospital, London; Massachusetts General Hospital, Boston; and the National Institutes of Health. After completion of his residency and fellowship, he served in several capacities in the Cardiology Branch of National Heart Lung and Blood Institute, NIH in Bethesda, MD, including Senior Investigator and Director of the Cardiac Catheterization Laboratory. In 2001 he was appointed Professor of Medicine in the Division of Cardiology at Emory University School of Medicine, and in 2010 he was named Co-Director of the Emory Clinical Cardiovascular Research Institute (ECCRI). Since 2005, Dr. Quyyumi has been awarded more than $9 million in research funding. He serves on the Editorial Boards of several national journals, is a member on several Scientific Advisory Boards, and is a reviewer for the NIH-NHLBI Study Sections. Dr. Quyyumi has authored more than 180 peer-reviewed publications and has been an invited speaker and session chair at numerous National and International scientific meetings and conferences.
Dr. Quyyumi’s research focus includes vascular biology, angiogenesis, progenitor cell biology, mechanisms of myocardial ischemia, and the role of genetic and environmental risks on vascular disease. Other interests have spanned the fields of personalized medicine and disparities in cardiovascular diseases. During his academic career, Dr. Quyyumi has carried out more than 50 NIH, industry-funded, or investigator-initiated projects, including numerous clinical trials.